ATYR
Price
$5.22
Change
+$0.05 (+0.97%)
Updated
Jun 20 closing price
Capitalization
464.6M
52 days until earnings call
IDYA
Price
$21.67
Change
-$0.19 (-0.87%)
Updated
Jun 20 closing price
Capitalization
1.9B
51 days until earnings call
Interact to see
Advertisement

ATYR vs IDYA

Header iconATYR vs IDYA Comparison
Open Charts ATYR vs IDYABanner chart's image
aTyr Pharma
Price$5.22
Change+$0.05 (+0.97%)
Volume$3.33M
Capitalization464.6M
IDEAYA Biosciences
Price$21.67
Change-$0.19 (-0.87%)
Volume$780.09K
Capitalization1.9B
ATYR vs IDYA Comparison Chart in %
Loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATYR vs. IDYA commentary
Jun 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATYR is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 22, 2025
Stock price -- (ATYR: $5.22 vs. IDYA: $21.67)
Brand notoriety: ATYR and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATYR: 185% vs. IDYA: 60%
Market capitalization -- ATYR: $464.6M vs. IDYA: $1.9B
ATYR [@Biotechnology] is valued at $464.6M. IDYA’s [@Biotechnology] market capitalization is $1.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $333.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.36B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATYR’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • ATYR’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, ATYR is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATYR’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 5 bullish TA indicator(s).

  • ATYR’s TA Score: 5 bullish, 4 bearish.
  • IDYA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ATYR is a better buy in the short-term than IDYA.

Price Growth

ATYR (@Biotechnology) experienced а +0.38% price change this week, while IDYA (@Biotechnology) price change was -2.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.57%. For the same industry, the average monthly price growth was +27.78%, and the average quarterly price growth was +14.34%.

Reported Earning Dates

ATYR is expected to report earnings on Aug 13, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+9.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.9B) has a higher market cap than ATYR($465M). ATYR YTD gains are higher at: 44.199 vs. IDYA (-15.681). ATYR has higher annual earnings (EBITDA): -65.9M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. ATYR (76.3M). ATYR has less debt than IDYA: ATYR (13M) vs IDYA (26M). IDYA has higher revenues than ATYR: IDYA (7M) vs ATYR (0).
ATYRIDYAATYR / IDYA
Capitalization465M1.9B24%
EBITDA-65.9M-356.46M18%
Gain YTD44.199-15.681-282%
P/E RatioN/AN/A-
Revenue07M-
Total Cash76.3M693M11%
Total Debt13M26M50%
FUNDAMENTALS RATINGS
ATYR vs IDYA: Fundamental Ratings
ATYR
IDYA
OUTLOOK RATING
1..100
4381
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
8764
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
3553
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (63) in the null industry is in the same range as ATYR (83). This means that IDYA’s stock grew similarly to ATYR’s over the last 12 months.

IDYA's Profit vs Risk Rating (64) in the null industry is in the same range as ATYR (87). This means that IDYA’s stock grew similarly to ATYR’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as ATYR (98). This means that IDYA’s stock grew similarly to ATYR’s over the last 12 months.

ATYR's Price Growth Rating (35) in the null industry is in the same range as IDYA (53). This means that ATYR’s stock grew similarly to IDYA’s over the last 12 months.

ATYR's P/E Growth Rating (100) in the null industry is in the same range as IDYA (100). This means that ATYR’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATYRIDYA
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 19 days ago
76%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BISVX13.220.01
+0.08%
Brown Advisory Sustainable Val Inv
PSMKX53.68-0.09
-0.17%
Victory Pioneer Select Mid Cap Growth R6
AILLX26.23-0.12
-0.46%
Aristotle Core Equity I-2
TILHX28.65-0.17
-0.59%
Nuveen Large Cap Growth I
GPGEX8.31-0.08
-0.95%
Grandeur Peak Global Explorer Instl

ATYR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATYR has been loosely correlated with MGTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ATYR jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATYR
1D Price
Change %
ATYR100%
+0.97%
MGTX - ATYR
44%
Loosely correlated
-2.16%
RZLT - ATYR
40%
Loosely correlated
+0.98%
SLDB - ATYR
40%
Loosely correlated
+3.01%
AURA - ATYR
39%
Loosely correlated
-0.98%
IDYA - ATYR
39%
Loosely correlated
-0.87%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-0.87%
IMNM - IDYA
60%
Loosely correlated
-0.91%
CGON - IDYA
60%
Loosely correlated
-2.78%
CRNX - IDYA
56%
Loosely correlated
N/A
XENE - IDYA
56%
Loosely correlated
+0.47%
COGT - IDYA
55%
Loosely correlated
-0.14%
More